
AC Immune and Takeda Enter Exclusive License Agreement for Amyloid Beta Immunotherapy in Alzheimer’s Disease
Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, global option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including…












